Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out. The FDA has ...

Recent FDA approvals have included Rubraca (rucaparib), which was approved in 2020 for patients with metastatic castration-resistant prostate cancer that expresses a BRCA mutation, and Lynparza ...

Scientists that discovered a life-saving drug to treat cancer patients with a faulty gene are marking a special anniversary, and looking back at the impact their work has had around the world.

A drug used against cancer could also be effective against severe coronavirus infection.

However, the approaches within these trials resemble the Olaparib trials. Rucaparib and Niraparib are being investigated in platinum sensitive ovarian cancers as a maintenance therapy (NCT01968213 ...

CENTRAL GOVERNMENT FUNDS: Social welfare would account for the largest portion of the NT$3.33 trillion budget, followed by spending on education, tech and culture ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Nov. 8, 2024 — Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if ...

November 4, 2024 • How did life start on Earth? The answer is a big scientific mystery scientists are actively investigating. After talking with many scientists, host Regina G. Barber found that ...

Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive ...

Foreign leaders have rushed to ingratiate themselves with Donald J. Trump in recent days, nervously recalling the clashes, insults and feuds of his first presidency. By Mark LandlerMatina Stevis ...

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596] Technology appraisal guidance TBC Rozanolixizumab for treating antibody-positive generalised ...